

# Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2020

<https://marketpublishers.com/r/N25BA74C3B28EN.html>

Date: October 2020

Pages: 60

Price: US\$ 3,500.00 (Single User License)

ID: N25BA74C3B28EN

## Abstracts

Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2020

### SUMMARY

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Nicotinamide phosphoribosyltransferase (NAmPRTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis. NAmPRTase catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity.

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Infectious Disease, Toxicology, Cardiovascular, Central Nervous System and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Multiple Myeloma (Kahler Disease), Pulmonary Radiation Toxicity, Waldenstrom Macroglobulinemia

(Lymphoplasmacytic Lymphoma), Acute Lung Injury, Acute Respiratory Distress Syndrome, Age Related Memory Impairment, Amyotrophic Lateral Sclerosis, Colon Cancer, Coronavirus Disease 2019 (COVID-19), Depression, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Leukemia, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Pulmonary Arterial Hypertension, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sarcomas, Solid Tumor, Traumatic Brain Injury and Triple-Negative Breast Cancer (TNBC).

The latest report Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2020, outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)

The report reviews Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects

The report assesses Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Overview

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Companies Involved in Therapeutics Development

AbbVie Inc

Aqualung Therapeutics Corp

Aurigene Discovery Technologies Ltd

Calico LLC

Eli Lilly and Co

Genentech USA Inc

Karyopharm Therapeutics Inc

OncoTartis Inc

Tianjin Hemay Pharmaceutical Co Ltd

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Drug Profiles

ALT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AU-4869 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enamptcumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNE-617 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hemay-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPT-9274 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSN-3154567 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OT-82 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P7-C3A20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NAMPT for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STF-118804 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing

Factor 1 or NAMPT or EC 2.4.2.12) - Dormant Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing

Factor 1 or NAMPT or EC 2.4.2.12) - Discontinued Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing

Factor 1 or NAMPT or EC 2.4.2.12) - Product Development Milestones

Featured News & Press Releases

Oct 19, 2020: Researchers discover neuroprotective treatment for chronic traumatic brain injury

Jun 02, 2020: Aqualung Therapeutics receives A \$2.3 million National Institute Of Health (NIH) Fast-Track award to develop a novel therapeutic antibody for patients with radiation-induced lung injury

May 27, 2020: Aqualung Therapeutics receives NIH approval to advance to IND-enabling studies via the STTR Fastrack Phase II award for development of a novel anti-inflammatory therapeutic antibody for ARDS and the critically ill

Apr 13, 2020: Antengene announces dosing of first patient in the ATG-019 (KPT-9274) phase 1 trial, a first-in-class dual inhibitor, for advanced solid tumors and non-hodgkin's lymphoma

Mar 18, 2020: Aqualung Therapeutics advances its investigational monoclonal antibody into IND-enabling studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)

Jan 16, 2020: International research collaboration reveals promising drug candidate for treatment of blood cancers

Dec 05, 2019: Aqualung Therapeutics to present new data at Biotech Showcase Investor Conference

Aug 20, 2019: Aqualung Therapeutics receives \$225 thousand dollar National Institute of Health (NIH) grant to establish biomarker panel for patients with acute respiratory distress syndrome

Aug 13, 2019: Aqualung Therapeutics submits patent application to USPTO

Aug 06, 2019: Aqualung Therapeutics filed patent for eNamptor

Jul 20, 2019: Aqualung Therapeutics provides update on eNamptor

Jul 13, 2019: Aqualung Therapeutics submits \$3 million Department of Defense grant for eNamptor

Jun 05, 2019: Aqualung Therapeutics receives a \$1.7 Million National Institute Of Health (NIH) Fastrack Award To develop an novel immune-based therapeutic antibody for critically ill patients with acute lung injury

Jun 04, 2019: Aqualung Therapeutics Corporation receives A \$1.7 million National Institute of Health (NIH) fastrack award to develop an novel immune-based therapeutic antibody for critically ill patients with acute lung injury

Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American

Association for Cancer Research 2018 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020  
Number of Products under Development by Therapy Areas, H2 2020  
Number of Products under Development by Indications, H2 2020  
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020  
Number of Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020 (Contd..1), H2 2020  
Products under Development by Companies, H2 2020 (Contd..2), H2 2020  
Number of Products under Investigation by Universities/Institutes, H2 2020  
Products under Investigation by Universities/Institutes, H2 2020  
Number of Products by Stage and Mechanism of Actions, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Pipeline by AbbVie Inc, H2 2020  
Pipeline by Aqualung Therapeutics Corp, H2 2020  
Pipeline by Aurigene Discovery Technologies Ltd, H2 2020  
Pipeline by Calico LLC, H2 2020  
Pipeline by Eli Lilly and Co, H2 2020  
Pipeline by Genentech USA Inc, H2 2020  
Pipeline by Karyopharm Therapeutics Inc, H2 2020  
Pipeline by OncoTartis Inc, H2 2020  
Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, H2 2020  
Dormant Projects, H2 2020  
Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

## I would like to order

Product name: Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/N25BA74C3B28EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N25BA74C3B28EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970